<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 14: Clinically Important Drug Interactions: Effect of other Drugs on Guanfacine Extended-Release</caption>
<col width="197"></col>
<col width="357"></col>
<col width="174"></col>
<tbody>
<tr>
<td stylecode="     Toprule         Lrule          Rrule     "> Concomitant Drug Name or<br/>Drug Class</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Clinical Rationale and Magnitude of Drug Interaction</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Clinical Recommendation</td>
</tr>
<tr>
<td stylecode="     Toprule         Lrule          Rrule     "> Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected<br/>resulting in an increase in exposure</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Consider dose reduction <content stylecode="italics">[see Dosage and administration (</content>
<content stylecode="italics">
<linkhtml href="#LINK_f14c0d71-a2b0-4bba-9fa0-1fe8c358846a">2.7</linkhtml>
</content>
<content stylecode="italics">)]</content>
</td>
</tr>
<tr>
<td stylecode="     Toprule         Lrule          Rrule     "> Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Guanfacine is primarily metabolized by CYP3A4 and its<br/>plasma concentrations can be significantly affected resulting in a decrease in exposure</td>
<td stylecode="     Toprule         Lrule          Rrule     "> Consider dose increase<br/>
<content stylecode="italics">[see Dosage and administration (</content>
<content stylecode="italics">
<linkhtml href="#LINK_f14c0d71-a2b0-4bba-9fa0-1fe8c358846a">2.7</linkhtml>
</content>
<content stylecode="italics">)]</content>
</td>
</tr>
</tbody>
</table>